EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 369 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... July 30, 2024 A More Treatable Kind of Metastatic Cancer? October 5, 2020 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 Load more HOT NEWS 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer Moxetumomab Approved by FDA for Hairy Cell Leukemia A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
